Carlsbad, CA, January 29, 2007 - Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, reports in the British Journal of Cancer (1) on proceedings from an international symposium on EpCAM, a target antigen the company has selected for two drug candidates. One is the human antibody adecatumumab (MT201), which has completed two phase 2a trials. The other one is MT110, a BiTE® molecule, which is in formal preclinical development. EpCAM is one of the most frequently and intensely expressed tumor-associated antigens known.
